Pretransplantation α-fetoprotein slope and milan criteria: Strong predictors of hepatocellular carcinoma recurrence after transplantation

Transplantation

Volumn 95, Issue 1, 2013, Pages 228-233

  Dumitra, Teodora C ^a   Dumitra, Sinziana ^a   Metrakos, Peter P ^a   Barkun, Jeffrey S ^a   Chaudhury, Prosanto ^a   Deschênes, Marc ^a   Paraskevas, Steven ^a   Hassanain, Mazen ^a   Tchervenkov, Jean I ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Fetoprotein slope; Hepatocellular carcinoma; Liver transplantation; Recurrence

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CHI SQUARE TEST; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FISHER EXACT TEST; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TUMOR VOLUME;

AGED; ALPHA-FETOPROTEINS; BIAS (EPIDEMIOLOGY); CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL;

EID: 84872084855     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31827743d7     Document Type: Article

References (25)

1. El-Serag HB. Hepatocellular carcinoma. N Engl JMed 2011; 365: 1118.
2. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693.
3. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394.
4. Toso C, Asthana S, Bigam DL, et al. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009; 49: 832.
5. Lim KC, Chow PK, Allen JC, et al. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg 2011; 254: 108.
6. Vibert E, Azoulay D, Hoti E, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010; 10: 129.
7. Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer 1989; 64: 1700.
8. Merani S, Majno P, Kneteman NM, et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol 2011; 55: 814.
9. Han K, Tzimas GN, Barkun JS, et al. Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol 2007; 21: 39.
10. Mazzaferro V, Bhoori S, Sposito C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 2011; 17(Suppl 2): S44.
11. Clavien PA, Lesurtel M, Bossuyt PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13: e11.
12. Yao FY, Kerlan RK, Hirose R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008; 48: 819.
13. Investigators TCotLITpC. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28: 751.
14. Chevret S, Trinchet JC, Mathieu D, et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999; 31: 133.
15. Leung TWT, Tang AMY, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system. Cancer 2002; 94: 1760.
16. Chan SL, Mo FKF, Johnson PJ, et al. Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. J Gastroenterol Hepatol 2011; 26: 340.
17. Chen CH, Lin ST, Kuo CL, et al. Clinical significance of elevated alpha-fetoprotein (AFP) in chronic hepatitis C without hepatocellular carcinoma. Hepatogastroenterology 2008; 55: 1423.
18. Poon RT, Fan ST, Lo CM, et al. Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg 2007; 245: 51.
19. DuBay D, Sandroussi C, Sandhu L, et al. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg 2011; 253: 166.
20. Pawlik TM, Gleisner AL, Anders RA, et al. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann Surg 2007; 245: 435.
21. Chau GY, Lui WY, Wu CW. Spectrum and significance of microscopic vascular invasion in hepatocellular carcinoma. Surg Oncol Clin N Am 2003; 12: 25, viii.
22. Parfitt JR, Marotta P, Alghamdi M, et al. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl 2007; 13: 543.
23. Dumitra TC, Tchervenkov J, Chaudhury P, et al. Serial measurement of pre-operative alpha-fetoprotein and its slope can be a predictor of HCC aggressiveness. Transplantation 2010; 90: 786.
24. Tamura S, Kato T, Berho M, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 2001; 136: 25; discussion 31.
25. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35.